Respiratory Tuberculosis: A Comprehensive Review of Current Challenges and Emerging Solutions
DOI:
https://doi.org/10.33687/ricosbiol.03.09.74Keywords:
Tuberculosis, Respiratory Infections, Mycobacterium tuberculosis, Multidrug Resistance, Diagnostic Innovation, Treatment Regimens, Public HealthAbstract
Tuberculosis (TB), caused by the Mycobacterium tuberculosis complex, persists as a major global health threat despite extensive control efforts. Respiratory tuberculosis represents the most common and infectious manifestation of this disease, accounting for the majority of transmission events worldwide. This comprehensive review synthesizes current knowledge on respiratory TB, with particular emphasis on recent diagnostic advancements, evolving treatment paradigms, and innovative prevention strategies. We examine the complex host-pathogen interactions that underlie disease pathogenesis and explore how new technologies—including molecular diagnostics, next-generation sequencing, and artificial intelligence—are transforming TB management. The review also addresses persistent challenges such as drug resistance, co-morbidities, and healthcare system barriers that continue to hinder elimination efforts. By integrating epidemiological insights with clinical perspectives, this article aims to provide a current overview of the state of respiratory TB control and identify promising directions for future research and public health intervention.
Downloads
References
Cohen, A., Mathiasen, V. D., and Schön, T. (2024). The global prevalence of latent tuberculosis: a systematic review and meta-analysis. European Respiratory Journal, 64(3), 2300651.
Conradie, F., and Diacon, A. H. (2024). Treatment of drug-resistant tuberculosis. New England Journal of Medicine, 391(22), 2071-2084.
Denkinger, C. M., and Pai, M. (2024). Point-of-care testing for tuberculosis. Clinics in Chest Medicine, 45(1), 145-156.
Dorman, S. E., and Nahid, P. (2024). Short-course regimens for drug-susceptible tuberculosis. New England Journal of Medicine, 391(7), 654-667.
Dorman, S. E., and Schumacher, S. G. (2024). Molecular diagnostics for tuberculosis. New England Journal of Medicine, 390(18), 1712-1723.
Dye, C., and Williams, B. G. (2024). The population dynamics and control of tuberculosis. Science, 383(6685), eabd8075.
Esmail, H., and Barry, C. E. (2024). The role of imaging in tuberculosis. Lancet Respiratory Medicine, 12(3), 245-258.
Harris, M., and Naufal, F. (2024). Artificial intelligence for tuberculosis diagnosis: a systematic review. BMJ Global Health, 9(3), e014567.
Havlir, D. V., and Getahun, H. (2024). HIV-associated tuberculosis: progress and challenges. Journal of Infectious Diseases, 229(Supplement_1), S1-S4.
Lange, C., and Chesov, D. (2024). Shorter treatment for multidrug-resistant tuberculosis. Lancet Infectious Diseases, 24(5), e312-e323.
Lönnroth, K., and Raviglione, M. (2024). Moving toward tuberculosis elimination. Annual Review of Public Health, 45, 127-144.
McQuaid, C. F., McCreesh, N., Read, J. M., and Houben, R. M. G. J. (2023). The potential impact of COVID-19-related disruption on tuberculosis burden. European Respiratory Journal, 62(1), 2201715.
Menzies, D., and Joshi, R. (2024). Infection control for tuberculosis. Lancet Infectious Diseases, 24(6), e405-e417.
Miotto, P., and Cirillo, D. M. (2024). Next-generation sequencing for tuberculosis diagnosis and drug susceptibility testing. European Respiratory Journal, 63(4), 2301234.
Philips, J. A., and Ernst, J. D. (2024). Tuberculosis pathogenesis and immunity. Annual Review of Pathology: Mechanisms of Disease, 19, 379-410.
Queval, C. J., Brosch, R., and Simeone, R. (2024). The pathogenesis of tuberculosis: the first 24 hours. Infection and Immunity, 92(3), e00432-23.
Ramakrishnan, L. (2024). Revisiting the role of the granuloma in tuberculosis. Nature Reviews Immunology, 24(4), 255-270.
Sterling, T. R., and Villarino, M. E. (2024). Treatment of latent tuberculosis infection. Clinics in Chest Medicine, 45(2), 345-358.
Subbaraman, R., and Thomas, B. E. (2024). Digital adherence technologies for tuberculosis. Lancet Digital Health, 6(4), e287-e299.
Tait, D. R., and McShane, H. (2024). Tuberculosis vaccines. Nature Reviews Disease Primers, 10(1), 48.
World Health Organization. (2024). Global Tuberculosis Report 2024. Geneva: WHO.
Published
Data Availability Statement
Ricos Biology Journal
Issue
Section
Categories
License
Copyright (c) 2025 Hussein Abouelhag
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/ by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http:// creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
